Kymera Therapeutics (KYMR) Net Cash Flow Growth (1y) (2020 - 2026)
Kymera Therapeutics (KYMR) Net Cash Flow Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,719.23 Bn | 65,718.94 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 470.97 Bn | 466.18 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 122.29 Bn | 115.05 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.43 Bn | 34.42 Bn | 959.66 Mn | 53.46% |
| 10 | Kymera Therapeutics | 10.79 Bn | 10.14 Bn | - | -603.21% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -603.21% |
| Dec 31, 2025 | 2,456.02% |
| Sep 30, 2025 | -617.79% |
| Jun 30, 2025 | 1,049.94% |
| Mar 31, 2025 | -84.14% |
| Dec 31, 2024 | -66.99% |
| Sep 30, 2024 | 50.21% |
| Jun 30, 2024 | -1,470.87% |
| Mar 31, 2024 | 9.78% |
| Dec 31, 2023 | 133.16% |
| Sep 30, 2023 | -63.61% |
| Jun 30, 2023 | -95.63% |
| Mar 31, 2023 | -27.92% |
| Dec 31, 2022 | 16.36% |
| Sep 30, 2022 | 9.50% |
| Jun 30, 2022 | 35.78% |
| Mar 31, 2022 | -164.48% |
| Dec 31, 2021 | -338.53% |
| Sep 30, 2021 | 1,227.40% |
| Jun 30, 2021 | 154.19% |